Diabetes type2
Conditions
Keywords
Intensive therapy, treatment de-escalation
Brief summary
Despite advances in diabetes management, many patients with type 2 diabetes in China fail to achieve optimal glycemic control. One of the possible reasons is associated with the delay in therapeutic decision making that lags behind glycemic rise. The investigators design this study and presume that using vildagliptin and metformin in combination with basal insulin as sequential treatment after intensive insulin therapy, might better modulate the dual islet hormone dysfunction than traditionally stepwise upgrading therapy pattern in patients with poorly controlled T2DM, and thus lead to a glucose normalization, β-cell function improvement and therapy simplification.
Detailed description
This is a multicenter, randomized, controlled, open-label, clinical superiority trial. The participants will be recruited from 10 centers in China. The enrolled participants will be randomly assigned into 3 groups, designated as Group A , B and C. Group A (CSII with wearables)：Continuous subcutaneous insulin infusion (CSII) will be applied to the participants for 1-2 weeks and thereafter the combination therapy of basal insulin, metformin and vildagliptin for the next 10 weeks and then insulin will be suspended. The participants are wearing wearables. Group B (CSII without wearbles): CSII will be applied to the participants for 1-2 weeks and thereafter the combination therapy of basal insulin, metformin and vildagliptin for the next 10 weeks and then insulin will be suspended. Group C (Basal insulin treatment): The participants will be applied the combination therapy of basal insulin, vildagliptin and metformin for the entire 12 weeks and then insulin will be suspended. Participants in both Group A, B and Group C will then receive combination therapy of metformin and vildagliptin, and be followed-up at the 16th, 20th, 24th, 28th, 32nd and 36th weeks. The doses of metformin and vildagliptin are set as 1.0\ 2.0g/d and 100mg/d, respectively. If the participants cannot tolerate metformin, then acarbose (50-100mg tid) or SGLT2 inhibitor can be instead used. If glucose is not well controlled, sulfonylureas or glinides can be added as a rescue treatment.
Interventions
DRUGCSII and thereafter combination therapy, followed up with wearable devices
Short-term continuous subcutaneous insulin infusion and thereafter the combination therapy of basal insulin, metformin and vildagliptin; Wearable devices will be used to manage and follow-up the participants.
DRUGCSII and thereafter combination therapy
Short-term continuous subcutaneous insulin infusion and thereafter the combination therapy of basal insulin, metformin and vildagliptin.
DRUGBasal insulin treatment without wearables
The participants will be applied the combination therapy of basal insulin, metformin and vildagliptin for the entire 12 weeks.
Sponsors
Yanbing Li
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
18 Years to 70 Years
Healthy volunteers
No
Inclusion criteria
1. Type 2 diabetes diagnosed according to WHO criteria (1999); With a duration of 1\~15 years; 2. With two or more oral hypoglycemic drugs, or basal insulin and 1-2 oral hypglycemic agents, used for at least 3 months; 3. HbA1c of 7.5 to 13% and fasting C-peptide \> 0.4 nmol/L; 4. Age of 18 to 70 years; 5. BMI of 20 to 35 kg/m²； 6. Capable of and willing to follow doctors' instructions to: * Self-monitor blood glucose according to the protocol; * Follow the protocol and have regular visits as required; ③ Record and maintain the research diary, as required by the protocol; ④ Keep contact with the investigators and receive phone calls during the study.
Exclusion criteria
1. Type 1 diabetes or specific types of diabetes; 2. Those who have received premixed insulin therapy and/or basal - meal insulin and/or basal insulin-oral hypoglycemic agents treatment accumulation for 7 days or more, and those who have received CSII therapy in the last one year, and those who have received GLP-1 analogue within 3 months before screening; 3. Those who have acute diabetic complications (diabetic ketoacidosis, hyperosmotic hyperglycemia coma or lactic acidosis); 4. Those who have severe diabetic microvascular complications (proliferative retinopathy, clinical proteinuria, and glomerular filtration rate less than 45 ml/min, uncontrolled diabetic neuropathy and obvious diabetic autonomic neuropathy); 5. Those with ALT \>2.5 times of the upper limit of normal (ULN), bilirubin \> 1.5 times of ULN； 6. Those with known macrovascular disease: Patients with acute cerebrovascular accident, acute coronary syndrome, unstable angina, peripheral artery disease who have received vascular intervention or amputation in the 12 months before enrollment; Or chronic cardiac dysfunction with cardiac function grade III or above; 7. Those with poor blood pressure control (systolic blood pressure≥160mmHg and/or sitting diastolic blood pressure ≥110mmHg) and inability to control under 160/110mmhg within 1 week; 8. Serious systemic disease or malignant tumor, chronic diarrhea, etc； 9. Those with drugs that may affect blood glucose for a cumulative time of more than 1 week within 12 weeks, such as oral/venous glucocorticoid, growth hormone, estrogen/ progesterone, high-dose diuretics, antipsychotic drugs. However, low-dose diuretics for antihypertensive purposes (HCTZ \< 25mg/d, indapamide \< 1.5mg/d) and physiologic dose of thyroid hormone for replacement therapy are not included； 10. Any factors that may affect the participation of the subject in the study or the evaluation of the results； 11. Pregnancy or planned pregnancy, lactation subjects.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| the proportions of treatment de-escalation | 24 weeks after the insulin treatment | the proportions of patients who can use only combination of two oral hypoglycemic agents |
Countries
China
Contacts
PRINCIPAL_INVESTIGATORYanbing Li, Dr
FAH-SYSU
Outcome results
None listed